ET-26HCl
Phase 3Small molecule
ET-26HCl is one of 46 small molecule programs targeting Sedation. It is currently in Phase 3.
2
Indications
4
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
119 competitors in Renal Insufficiency
#DrugCompanyPhaseTrials
1Galvus
NovartisPhase 3
Afinitor
NovartisPhase 3
Januvia
ZZydus Therapeutics Inc.
Phase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Calcineurin Inhibitors
SanofiPhase 3
Cysteine Hydrochloride
NovartisPhase 2
Velcade
SShilpa Grover, MD, MPH
Phase 2
Decadron
AAspen Global Incorporated
Phase 2
Pomalyst
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Tradjenta
Boehringer IngelheimPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Elderly1 trial
Sedation1 trial
Efficacy and Safety1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ET-26HCl. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AAhon Pharmaceutical Co., Ltd.